CLINICAL_TRIALS
trial_result
· 2014-12-19
Clinical Trial Update: Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma [Phase 2]
Summary
Phase 2 study evaluating Bay 59-8862 in patients with advanced renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED